Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, ...
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Securities
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...
Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen
Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...
Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They ...
Investing3d
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen
On Tuesday, TD Cowen analysts lowered the stock rating for Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold. The change comes following the company’s receipt of a Complete Response Letter (CRL ...
Investing3d
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen
On Tuesday, TD Cowen analysts lowered the stock rating for Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold. The change comes following the company’s receipt of a Complete Response ...
Emcure subsidiary Tillomed Laboratories to acquire UK based Manx Healthcare and its subsidiaries
Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare and its subsidiaries, Manx Pharma and Manx Generics ...
Tillomed acquires Manx Healthcare’s pharma portfolio for £19.7 million
Tillomed Labs acquires Manx Healthcare's portfolio, expanding market reach and diversifying product line in the ...
Rediff Money10h
Tillomed Acquires Manx Healthcare Portfolio for £19.7 Million
Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has acquired the product portfolio of UK-based Manx Healthcare for approximately £19.7 million, expanding its product offerings and ...
Pharmaceutical Technology3d
CNS market resurgence: a decade-long slump ends with $80bn milestone
In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...